Emerging markets have seen progress on back of an uptick in vaccination rollouts, but the recent Chinese regulatory crackdown and further virus outbreaks have caused equities to generally underperform year to date relative to developed markets. With a focus on emerging markets outside of Asia, Franklin Templeton’s Emerging Markets Equity Senior Managing Director Chetan Sehgal nonetheless remains bullish on the long-term potential of emerging markets and outlines three main reasons: debt, valuations and cashflows. READ MORE
Similar Posts:
- Which Emerging Markets May Benefit Most from the Rebound in China and the DM? (PGIM Fixed Income)
- Why China’s Stock Market Tumble is Giving India’s a Lift (Nikkei Asia)
- China Venture Capital Deals Shrink Amid Regulatory Concerns (Nikkei Asia)
- Are Emerging Markets Recoupling with Developed Markets? (II)
- Beijing’s Regulatory Crackdown Is Unlikely to End Any Time Soon (CIGI)
- Why Now Might be a Good Time for Risk-Tolerant Investors to Buy Into Emerging Markets (Globe and Mail)
- 2018 Emerging Markets Outlook: Rally In EM Equities to Continue – Particularly for Emerging Asia (Fiera Capital)
- Is This Divergence an Emerging Market Warning Sign? (BCA Research)
- Where to Find Opportunities in Emerging Markets (BlackRock)
- All Regions in the Recovery Stage of their Economic Cycles (Candriam)
- Outlook On Emerging Markets (Lazard AM)
- Why it Could Be a Big Year for Chinese Bank Stocks (The Asset)
- Quarterly Frontier Markets Recap 2Q21 (FitchRatings)
- Will Meituan Become Hong Kong’s Tesla? (The Asset)
- Portfolio Money Flows Back Into the Philippines (WSJ)
